Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Anivamersen; Pegnivacogin; Pegnivacogin/anivamersen; RB 006; RB 006/RB 007; RB 007; REG-1; REG-2; Revolixys

Latest Information Update: 14 Nov 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archemix Corporation
  • Developer Tobira Therapeutics
  • Class Anticoagulants; Antidotes; Antithrombotics; Nucleotide aptamers; Oligonucleotides
  • Mechanism of Action Factor IXa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Venous thrombosis

Most Recent Events

  • 01 Nov 2016 Tobira Therapeutics has been acquired by Allergan
  • 05 May 2015 Regado Biosciences has merged with Tobira Therapeutics and renamed Tobira Therapeutics
  • 25 Aug 2014 Regado Biosciences permanently terminates enrolment in the phase III REGULATE-PCI trial (NCT01848106)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top